Assessment of mumps virus-specific antibodies by different serological assays: which test correlates best with mumps immunity?

  • R. AllwinnEmail author
  • B. Zeidler
  • K. Steinhagen
  • E. Rohwäder
  • S. Wicker
  • H. F. Rabenau
  • H. W. Doerr


Mumps is one of the vaccine-preventable childhood diseases and it has not yet been eradicated in Germany. This raises the question as to whether the available mumps vaccines are effective enough to prevent mumps and which antibody test system allows the authentic assigning of mumps-specific immunity. In an attempt to answer this question, we analysed 227 sera samples from medical students of the University Hospital Frankfurt/Main, Germany, using different test systems: indirect immune fluorescence, neutralisation assay, routine ELISA and newly developed immunoassays, which contain the mumps nucleoprotein and the wild-type strain Enders ATCC VR106, respectively. Mumps vaccination coverage of the screened collective amounted to 75.1%, which differs notably from the detected mumps-specific seropositivity rates in the literature (range 53.3% to 82.4%). In contrast, a small group of unvaccinated students had much higher seropositivity rates. Of course, assigned vaccination coverage and calculated seropositivity rates are not effective enough to interrupt the transmission of the mumps virus. The often-occurring mumps outbreaks, some in highly vaccinated populations, may not always demonstrate vaccine failure. The investigation of newly developed test systems and the occurrence of different mumps virus genotypes should also be considered.


Vaccination Coverage Mumps Seroprevalence Rate Seropositivity Rate Mumps Virus 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



We highly appreciate the excellent technical assistance of Mrs. Gabriele Bauer and Mrs. Cornelia Rühl, and would like to express our most sincere thanks to Dr. Joseph Allen Hockley for carefully proofreading the manuscript.

Source of support

We would like to thank EUROIMMUN for their encouragement and for the allocation of the serological test kits.


  1. 1.
    Stein-Zamir C, Shoob H, Abramson N, Tallen-Gozani E, Sokolov I, Zentner G (2009) Mumps outbreak in Jerusalem affecting mainly male adolescents. Euro Surveill 14(50):pii=19440PubMedGoogle Scholar
  2. 2.
    Whelan J, van Binnendijk R, Greenland K, Fanoy E, Khargi M, Yap K, Boot H, Veltman N, Swaan C, van der Bij A, de Melker H, Hahné S (2010) Ongoing mumps outbreak in a student population with high vaccination coverage, Netherlands, 2010. Euro Surveill 15(17):pii=19554PubMedGoogle Scholar
  3. 3.
    Dayan GH, Rubin S (2008) Mumps outbreaks in vaccinated populations: are available mumps vaccines effective enough to prevent outbreaks? Clin Infect Dis 47:1458–1467PubMedCrossRefGoogle Scholar
  4. 4.
    Briss PA, Fehrs LJ, Parker RA, Wright PF, Sannella EC, Hutcheson RH, Schaffner W (1994) Sustained transmission of mumps in a highly vaccinated population: assessment of primary vaccine failure and waning vaccine-induced immunity. J Infect Dis 169(1):77–82PubMedCrossRefGoogle Scholar
  5. 5.
    Cohen C, White JM, Savage EJ, Glynn JR, Choi Y, Andrews N, Brown D, Ramsay ME (2007) Vaccine effectiveness estimates, 2004–2005 mumps outbreak, England. Emerg Infect Dis 13(1):12–17PubMedGoogle Scholar
  6. 6.
    Cortese MM, Jordan HT, Curns AT, Quinlan PA, Ens KA, Denning PM, Dayan GH (2008) Mumps vaccine performance among university students during a mumps outbreak. Clin Infect Dis 46(8):1172–1180PubMedCrossRefGoogle Scholar
  7. 7.
    Kaaijk P, van der Zeijst BA, Boog MC, Hoitink CW (2008) Increased mumps incidence in the Netherlands: review on the possible role of vaccine strain and genotype. Euro Surveill 13(26):pii=18914PubMedGoogle Scholar
  8. 8.
    World Health Organization (WHO) (2007) Mumps virus vaccines. Wkly Epidemiol Rec 82(7):51–60Google Scholar
  9. 9.
    Schlegel M, Osterwalder JJ, Galeazzi RL, Vernazza PL (1999) Comparative efficacy of three mumps vaccines during disease outbreak in Eastern Switzerland: cohort study. BMJ 319(7206):352PubMedGoogle Scholar
  10. 10.
    Peltola H, Kulkarni PS, Kapre SV, Paunio M, Jadhav SS, Dhere RM (2007) Mumps outbreaks in Canada and the United States: time for new thinking on mumps vaccines. Clin Infect Dis 45(4):459–466PubMedCrossRefGoogle Scholar
  11. 11.
    Quast U, Arndt U (2009) Masern-, Mumps-, Röteln- und Varizellenimpfung bei Jugendlichen und Erwachsenen—eine Übersicht. Dtsch Med Wochenschr 134:S77–S81PubMedCrossRefGoogle Scholar
  12. 12.
    Santos CL, Ishida MA, Foster PG, Sallum MA, Benega MA, Borges DB, Corrêa KO, Constantino CR, Afzal MA, Paiva TM (2008) Detection of a new mumps virus genotype during parotitis epidemic of 2006–2007 in the state of São Paulo, Brazil. J Med Virol 80(2):323–329PubMedCrossRefGoogle Scholar
  13. 13.
    Mühlemann K (2004) The molecular epidemiology of mumps virus. Infect Genet Evol 4(3):215–219PubMedCrossRefGoogle Scholar
  14. 14.
    Rubin SA, Qi L, Audet SA, Sullivan B, Carbone KM, Bellini WJ, Rota PA, Sirota L, Beeler J (2008) Antibody induced by immunization with the Jeryl Lynn mumps vaccine strain effectively neutralizes a heterologous wild-type mumps virus associated with a large outbreak. J Infect Dis 198(4):508–515PubMedCrossRefGoogle Scholar
  15. 15.
    Steinhagen K, Biermann-Göcke S, Dönig M, Zein M, Schlumberger W, Stöcker W (2008) Mumps-spezifische Immunität etabliert sich erst 120 Tage nach MMR-Impfung! Antikörper-Bestimmung unter Verwendung von Antigenen des Impfstammes anstelle des Wildtyps. Pädiatrie hautnah 3.2008; 173 (abstract band, 16. DGPI congress)Google Scholar
  16. 16.
    Rabenau HF, Marianov B, Wicker S, Allwinn R (2007) Comparison of the neutralizing and ELISA antibody titres to measles virus in human sera and in gamma globulin preparations. Med Microbiol Immunol 196(3):151–155PubMedCrossRefGoogle Scholar
  17. 17.
    Buxbaum S, Doerr HW, Allwinn R (2001) Epidemiological analysis of immunity against vaccine-preventable diseases: rubella, measles, mumps and chickenpox. Dtsch Med Wochenschr 126:1289–1293PubMedCrossRefGoogle Scholar
  18. 18.
    Poethko-Müller C, Kuhnert R, Schlaud M (2007) Durchimpfung und Determinanten des Impfstatus in Deutschland. Ergebnisse des Kinder- und Jugendgesundheitssurveys (KIGGS). Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 50:851–862PubMedCrossRefGoogle Scholar
  19. 19.
    Wicker S, Rabenau HF, Gottschalk R, Doerr HW, Allwinn R (2007) Seroprevalence of vaccine preventable and blood transmissible viral infections (measles, mumps, rubella, polio, HBV, HCV and HIV) in medical students. Med Microbiol Immunol 196:145–150PubMedCrossRefGoogle Scholar
  20. 20.
    Nokes DJ, Anderson RM (1988) Measles, mumps, and rubella vaccine: what coverage to block transmission? Lancet 2:1374PubMedCrossRefGoogle Scholar
  21. 21.
    Vainio K, Samdal HH, Anestad G, Wedege E, Skutlaberg DH, Bransdal KT, Mundal R, Aaberge IS (2008) Detection of measles- and mumps-specific IgG antibodies in paired serum and oral fluid samples from Norwegian conscripts. Eur J Clin Microbiol Infect Dis 27(6):461–465PubMedCrossRefGoogle Scholar
  22. 22.
    Jokinen S, Österlund P, Julkunen I, Davidkin I (2007) Cellular immunity to mumps virus in young adults 21 years after measles-mumps-rubella vaccination. J Infect Dis 196:861–867PubMedCrossRefGoogle Scholar
  23. 23.
    Brockhoff HJ, Mollema L, Sonder GJ, Postema CA, van Binnendijk RS, Kohl RH, de Melker HE, Hahné SJ (2010) Mumps outbreak in a highly vaccinated student population, The Netherlands, 2004. Vaccine 28(17):2932–2936PubMedCrossRefGoogle Scholar
  24. 24.
    Centers for Disease Control and Prevention (CDC) (2010) Update: mumps outbreak—New York and New Jersey, June 2009–January 2010. MMWR Morb Mortal Wkly Rep 59(5):125–129Google Scholar
  25. 25.
    Echevarría JE, Castellanos A, Sanz JC, Pérez C, Palacios G, Martínez de Aragón MV, Peña Rey I, Mosquera M, de Ory F, Royuela E (2010) Circulation of mumps virus genotypes in Spain from 1996 to 2007. J Clin Microbiol 48(4):1245–1254PubMedCrossRefGoogle Scholar
  26. 26.
    Castilla J, García Cenoz M, Arriazu M, Fernández-Alonso M, Martínez-Artola V, Etxeberria J, Irisarri F, Barricarte A (2009) Effectiveness of Jeryl Lynn-containing vaccine in Spanish children. Vaccine 27:2089–2093PubMedCrossRefGoogle Scholar
  27. 27.
    Castilla J, García Cenoz M, Barricarte A, Irisarri F, Núñez-Córdoba JM, Barricarte A (2007) Mumps outbreak in Navarre region, Spain, 2006–2007. Euro Surveill 12(2):E070215.1PubMedGoogle Scholar
  28. 28.
    Ennis FA (1969) Immunity to mumps in an institutional epidemic. Correlation of insusceptibility to mumps with serum plaque neutralizing and hemagglutination-inhibiting antibodies. J Infect Dis 119(6):654–657PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • R. Allwinn
    • 1
    Email author
  • B. Zeidler
    • 1
  • K. Steinhagen
    • 2
  • E. Rohwäder
    • 2
  • S. Wicker
    • 3
  • H. F. Rabenau
    • 1
  • H. W. Doerr
    • 1
  1. 1.Institute of Medical Virology and Travel Vaccination CentreJ. W. Goethe University Hospital Frankfurt/MainFrankfurt/MainGermany
  2. 2.EUROIMMUN, Medizinische Labordiagnostika AGLübeckGermany
  3. 3.Occupational Health ServiceJohann Wolfgang Goethe-UniversityFrankfurt am MainGermany

Personalised recommendations